ABVC BioPharma, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from ABVC BioPharma, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Shareholder Slice Ratio: Share count rose 640% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than 88% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
1/3 · 2/3Sales grew in 1 of the last 3 years; profit grew in 2 of 3.
Steadier than 50% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 100%
Sales fell 100% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-100% / +120%In 3 years sales changed by -100% while total assets changed by +120%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-1.9×Operating cash was negative last year, while some debt falls due within a year.
Higher than 64% of Healthcare companies in United States.
Cash Cushion Ratio
−10%Debt, after subtracting cash, equals 10% of its market value (net debt).
Lower than 78% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (11)
ABVC BioPharma, Inc. made a loss over the last year. ABVC BioPharma, Inc. owes $0.37 for every $1 it owns. ABVC BioPharma, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossABVC BioPharma, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
2.72The share price is 2.72 times ABVC BioPharma, Inc.'s book value per share, higher than 52% of Healthcare companies in United States.
Market cap
$28 MThe total market value of all of ABVC BioPharma, Inc.'s shares at today's price (share price × number of shares), smaller than 80% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$10 MWhat ABVC BioPharma, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.39Net worth divided by the number of shares. The share price of $1.05 is 2.7 times this, which is the P/B above.
Return on equity (ROE)
-69.9%ABVC BioPharma, Inc. lost 69.9% of its shareholders' money over the last year, lower than 61% of Healthcare companies in United States.
Owes vs Owns
0.37×ABVC BioPharma, Inc. owes $0.37 for every $1 it owns (low), lower than 54% of Healthcare companies in United States.
Dividend yield
NoneABVC BioPharma, Inc. does not currently pay a dividend.
Profit growth
LossABVC BioPharma, Inc. made a loss in each of the last two years.
Interest cover
Not coveredABVC BioPharma, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net debtABVC BioPharma, Inc. had $3 M more debt than cash (net debt) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For ABVC BioPharma, Inc.: $28 M ÷ $10 M (30 Jun 2026) = 2.7.
What is ABVC BioPharma, Inc.'s return on equity?
ABVC BioPharma, Inc. lost 69.9% of its shareholders' money over the last year, lower than 61% of Healthcare companies in United States.
How much does ABVC BioPharma, Inc. owe compared with what it owns?
ABVC BioPharma, Inc. owes $0.37 for every $1 it owns (low), lower than 54% of Healthcare companies in United States.
Does ABVC BioPharma, Inc. pay a dividend?
No. ABVC BioPharma, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.